Navigation Links
Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Date:2/25/2013

olumes of a medication under the skin and may result in faster administration times versus intravenously (IV) administered MabThera.
  • MabThera Positive Trials: Announced positive results from Roche's SABRINA and SparkThera studies, which showed that a fixed dose of MabThera can be administered subcutaneously, potentially allowing patients to spend less time in infusion centers receiving their MabThera treatment. Specifically, the studies showed that subcutaneous injection resulted in non-inferior MabThera concentrations in the blood compared with standard IV infusion.
  • Fourth Quarter and Year End 2012 Financial ResultsThe net loss for the fourth quarter of 2012 was $4.4 million, or $0.04 per share, compared with a net loss for the fourth quarter of 2011 of $18.4 million, or $0.18 per share. The net loss for the year ended December 31, 2012 was $53.6 million, or $0.48 per share, compared to a net loss of $19.8 million, or $0.19 per share for the comparable period in 2011.

  • Revenues for the fourth quarter of 2012 were $21.8 million, compared to $2.4 million for the fourth quarter of 2011. Revenues in the fourth quarter of 2012 included license fees revenue from Pfizer of $9.5 million and a milestone payment from Roche of $4 million.
  • Research and development expenses for the fourth quarter of 2012 were $18.6 million, compared with $14.9 million for the fourth quarter of 2011. The increase was due primarily to an increase in manufacturing activities to support potential launches from our collaborators.
  • Selling, general and administrative expenses for the fourth quarter of 2012 were $7.0 million, compared to $5.9 million for the fourth quarter of 2011.
  • Cash and cash equivalents were $99.9 million as of December 31, 2012, which includes net proceeds of $29.7 million from a term loan with Oxford Finance and Silicon Vall
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
    2. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    3. Halozyme to Host Third Quarter Financial Results Conference Call
    4. Halozyme Reports Second Quarter 2012 Financial Results
    5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
    6. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
    7. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    8. Halozyme Reports First Quarter 2012 Financial Results
    9. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    10. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
    11. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... 2014 Capnia, Inc. (NASDAQ: ... diagnostics based on its proprietary Sensalyze™ Technology Platform ... financial results for the third quarter and nine ... the completion of our initial public offering (IPO), ... recently initiated CoSense® commercial launch," said Anish Bhatnagar, ...
    (Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
    (Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
    Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
    ... Nov. 5, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... providing further clarity and context surrounding the risk ... occur with KRYSTEXXA® (pegloticase) in the treatment of ... at the American College of Rheumatology (ACR) Annual ...
    ... Volcano Corporation (NASDAQ: VOLC ), a ... designed to enhance the treatment of coronary and peripheral ... ( AD enosine V asodilator I ndependent ... by Volcano, will be presented in a Late-Breaking Session ...
    Cached Medicine Technology:Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 2Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 3Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 4Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 5Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 6Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 7Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 8Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 2Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 3Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 4
    (Date:12/19/2014)... December 20, 2014 These vanadium reserves ... other nations. Around 151,000 tons of vanadium were produced ... global vanadium usage increased at 6.7% AAGR during the ... and iron industry, being the largest consumer, accounted for ... followed by titanium-vanadium alloy and the chemical industry. , ...
    (Date:12/19/2014)... News) -- The intestinal bacteria that cause inflammatory bowel ... be inherited, researchers report. The findings, published recently ... in efforts to prevent the disease and treat the ... authors added. "The intestinal bacteria, or ,gut microbiome, ... a big impact on your health for the rest ...
    (Date:12/19/2014)... (HealthDay News) -- The cost of cancer treatment can ... study finds. Researchers examined data from 1,000 people ... colorectal or lung cancer. Of those patients, almost 900 ... than 100 had advanced cancer. Nearly half of ... medical bills, which was linked with a poorer health-related ...
    (Date:12/19/2014)... Kan. (PRWEB) December 19, 2014 B. ... exclusively to healthcare providers, has been retained to lead ... Estes Park Medical Center in Estes Park, Colo. The ... E. Smith has recently placed more than 900 healthcare ... (EPMC) is a 25-bed, not-for-profit critical access hospital and ...
    (Date:12/19/2014)... (PRWEB) December 19, 2014 Pain Free ... is excited to announce a new Superior magnetic ... magnets. These are the strongest neodymium magnets for the ... Free Living developed the Superior Magnetics brand for the ... Free Living performs magnetic therapy using Superior Magnetic Jewelry ...
    Breaking Medicine News(10 mins):Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2
    ... -- If you are one of the many people who ... steps can help reduce your stress on Thanksgiving. Mary ... at Binghamton University, State University of New York, offers the ... of time and have a list ready for what you ...
    ... HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) -- ... has spread to the lymph nodes could prevent many unnecessary ... is usually done via a major operation called a thoracotomy. ... operation can remove the cancer. However, if the cancer has ...
    ... HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) -- ... almost 44 percent in those at highest risk for contracting the ... study finds. The reduction in risk climbed to nearly 73 ... percent of the time, the researchers added. Truvada is already ...
    ... Reinberg HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay ... of the year, many Americans will soon be subjected to ... rising tide of concerns and complaints in recent weeks over ... machines is too low to pose any serious health threat. ...
    ... (Nov. 23, 2010) Breast cancer stem cells (CSCs), the aggressive ... which promote metastasis, are stimulated by estrogen via a pathway ... were able to halt the expansion of breast CSCs, a ... done in mice, is published in the Proceedings of ...
    ... -- Ferrography, a practice used by the American and ... extracts tiny iron particles from lubricants such as oil ... a system requires preventative maintenance can be the key ... University scientists are exploring a modification of this technique ...
    Cached Medicine News:Health News:Less Invasive Lung Cancer Staging Looks Promising 2Health News:Less Invasive Lung Cancer Staging Looks Promising 3Health News:Daily Pill Lowers Odds for Infection With HIV 2Health News:Daily Pill Lowers Odds for Infection With HIV 3Health News:Daily Pill Lowers Odds for Infection With HIV 4Health News:Airport Body Scanners Safe, Experts Say 2Health News:Airport Body Scanners Safe, Experts Say 3Health News:Discovery halts breast cancer stem cells 2Health News:Monitoring wear in helicopters -- and hips, knees and ankles, too 2Health News:Monitoring wear in helicopters -- and hips, knees and ankles, too 3
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: